新诊断1型糖尿病患者的肠道微生物组变化与血糖控制相关:一项INNODIA研究
该研究对98例新诊断1型糖尿病患者和194例自身抗体阳性未患病家庭成员进行宏基因组测序,随访2至4年。结果显示,新诊断患者中21种细菌物种纵向增加,普拉梭菌相对丰度与诊断时HbA1c水平呈负相关(p=0.0019);C肽快速下降者肠道微生物多样性最低;未患病家庭成员中19例进展为1型糖尿病者Sutterella sp. KLE1602丰度增加(p=1.2×10⁻⁴)。作者认为肠道微生物组组成与近期起病1型糖尿病的疾病进展相关,需进一步研究验证其意义和因果关系。
要点
- 新诊断1型糖尿病患者中21种细菌物种纵向增加,未患病家庭成员中未观察到。
- 普拉梭菌相对丰度与诊断时HbA1c水平呈负相关(p=0.0019)。
- C肽快速下降者肠道微生物多样性最低;进展为1型糖尿病的未患病家庭成员Sutterella sp. KLE1602丰度增加(p=1.2×10⁻⁴)。
核心结论
- 肠道微生物组组成与近期起病1型糖尿病的疾病进展相关,需进一步机制研究、动物研究和人体试验验证这些关联的意义和因果关系。
研究设计与样本
- 研究为INNODIA自然史研究的亚组分析,采用宏基因组测序分析肠道微生物组组成,纳入98例新诊断1型糖尿病患者(ND队列)和194例自身抗体阳性未患病家庭成员(UFM队列)。
主要发现
- ND队列中21种细菌物种纵向增加,UFM队列中未观察到。
- 普拉梭菌相对丰度与诊断时HbA1c水平呈负相关(p=0.0019)。
- ND队列中HbA1c、C肽水平和胰岛素剂量的变化所反映的后续疾病进展速率与多种细菌物种的丰度相关。
- ND队列中C肽水平快速下降者肠道微生物多样性最低。
- UFM队列中19例诊断为1型糖尿病者与未诊断的UFM个体相比Sutterella sp. KLE1602丰度增加(p=1.2×10⁻⁴)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步的机制研究、动物研究和人体试验来验证这些关联的意义和因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The gut microbiome is implicated in the disease process leading to clinical type 1 diabetes, but less is known about potential changes in the gut microbiome after the diagnosis of type 1 diabetes and implications in glucose homeostasis. We aimed to analyse potential associations between the gut microbiome composition and clinical and laboratory data during a 2 year follow-up of people with newly diagnosed type 1 diabetes, recruited to the Innovative approaches to understanding and arresting type 1 diabetes (INNODIA) study. In addition, we analysed the microbiome composition in initially unaffected family members, who progressed to clinical type 1 diabetes during or after their follow-up for 4 years. METHODS: We characterised the gut microbiome composition of 98 individuals with newly diagnosed type 1 diabetes (ND cohort) and 194 autoantibody-positive unaffected family members (UFM cohort), representing a subgroup of the INNODIA Natural History Study, using metagenomic sequencing. Participants from the ND cohort attended study visits within 6 weeks from the diagnosis and 3, 6, 12 and 24 months later for stool sample collection and laboratory tests (HbA1c, C-peptide, diabetes-associated autoantibodies). Participants from the UFM cohort were assessed at baseline and 6, 12, 18, 24 and 36 months later. RESULTS: We observed a longitudinal increase in 21 bacterial species in the ND cohort but not in the UFM cohort. The relative abundance of Faecalibacterium prausnitzii was inversely associated with the HbA1c levels at diagnosis (p=0.0019). The rate of the subsequent disease progression in the ND cohort, as assessed by change in HbA1c, C-peptide levels and insulin dose, was associated with the abundance of several bacterial species. Individuals with rapid decrease in C-peptide levels in the ND cohort had the lowest gut microbiome diversity. Nineteen individuals who were diagnosed with type 1 diabetes in the UFM cohort had increased abundance of Sutterella sp. KLE1602 compared with the undiagnosed UFM individuals (p=1.2 × 10-4). CONCLUSIONS/INTERPRETATION: Our data revealed associations between the gut microbiome composition and the disease progression in individuals with recent-onset type 1 diabetes. Future mechanistic studies as well as animal studies and human trials are needed to further validate the significance and causality of these associations.
引用
- Vatanen T, de Beaufort C, Marcovecchio ML, et al. Gut microbiome shifts in people with type 1 diabetes are associated with glycaemic control: an INNODIA study. Diabetologia. 2024. PMID: 38832971. doi:10.1007/s00125-024-06192-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。